These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 21916914)

  • 1. The contribution of NT-gp96 as an adjuvant for increasing HPV16 E7-specific immunity in C57BL /6 mouse model.
    Mohit E; Bolhassani A; Zahedifard F; Taslimi Y; Rafati S
    Scand J Immunol; 2012 Jan; 75(1):27-37. PubMed ID: 21916914
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immuno-Stimulating Peptide Derived from HMGB1 is More Effective Than the N-Terminal Domain of Gp96 as an Endogenous Adjuvant for Improvement of Protein Vaccines.
    Talebi S; Bolhassani A; Azad TM; Arashkia A; Modaresi MH
    Protein Pept Lett; 2017; 24(3):190-196. PubMed ID: 28000571
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Different domains of glycoprotein 96 influence HPV16 E7 DNA vaccine potency via electroporation mediated delivery in tumor mice model.
    Daemi A; Bolhassani A; Rafati S; Zahedifard F; Hosseinzadeh S; Doustdari F
    Immunol Lett; 2012 Dec; 148(2):117-25. PubMed ID: 23085605
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced immunogenicity of HPV16E7 accompanied by Gp96 as an adjuvant in two vaccination strategies.
    Bolhassani A; Zahedifard F; Taghikhani M; Rafati S
    Vaccine; 2008 Jun; 26(26):3362-70. PubMed ID: 18471945
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunomodulatory effects of IP-10 chemokine along with PEI600-Tat delivery system in DNA vaccination against HPV infections.
    Mohit E; Bolhassani A; Zahedifard F; Seyed N; Eslamifar A; Taghikhani M; Samimi-Rad K; Rafati S
    Mol Immunol; 2013 Jan; 53(1-2):149-60. PubMed ID: 22926003
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prophylactic and therapeutic efficacy of an attenuated Listeria monocytogenes-based vaccine delivering HPV16 E7 in a mouse model.
    Jia Y; Yin Y; Duan F; Fu H; Hu M; Gao Y; Pan Z; Jiao X
    Int J Mol Med; 2012 Dec; 30(6):1335-42. PubMed ID: 23027427
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Strong immune responses induced by a DNA vaccine containing HPV16 truncated E7 C-terminal linked to HSP70 gene.
    Meshkat Z; Soleimanjahi H; Mirshahabi H; Meshkat M; Kheirandish M; Hassan ZM
    Iran J Immunol; 2011 Jun; 8(2):65-75. PubMed ID: 21705833
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel fusion protein-based vaccine comprising a cell penetrating and immunostimulatory peptide linked to human papillomavirus (HPV) type 16 E7 antigen generates potent immunologic and anti-tumor responses in mice.
    Granadillo M; Vallespi MG; Batte A; Mendoza O; Soria Y; Lugo VM; Torrens I
    Vaccine; 2011 Jan; 29(5):920-30. PubMed ID: 21145912
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel therapeutic fusion protein vaccine by two different families of heat shock proteins linked with HPV16 E7 generates potent antitumor immunity and antiangiogenesis.
    Liu B; Ye D; Song X; Zhao X; Yi L; Song J; Zhang Z; Zhao Q
    Vaccine; 2008 Mar; 26(10):1387-96. PubMed ID: 18272260
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasmid encoding papillomavirus Type 16 (HPV16) DNA constructed with codon optimization improved the immunogenicity against HPV infection.
    Cheung YK; Cheng SC; Sin FW; Xie Y
    Vaccine; 2004 Dec; 23(5):629-38. PubMed ID: 15542183
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Protective immune responses induced by a recombinant Listeria monocytogenes delivering HPV16 E7].
    Jia Y; Yin Y; Tan W; Fu H; Chen X; Pan Z; Jiao X
    Wei Sheng Wu Xue Bao; 2012 Dec; 52(12):1508-14. PubMed ID: 23457800
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced anti-tumor effects of HPV16E7(49-57)-based vaccine by combined immunization with poly(I:C) and oxygen-regulated protein 150.
    Chen S; Ou R; Tang J; Deng X; Wu Y; van Velkinburgh JC; Ni B; Xu Y
    Cancer Epidemiol; 2013 Apr; 37(2):172-8. PubMed ID: 23127963
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of six cell penetrating peptides with different properties for in vitro and in vivo delivery of HPV16 E7 antigen in therapeutic vaccines.
    Shahbazi S; Bolhassani A
    Int Immunopharmacol; 2018 Sep; 62():170-180. PubMed ID: 30015237
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibody detection against HPV16 E7 & GP96 fragments as biomarkers in cervical cancer patients.
    Bolhassani A; Zahedifard F; Taslimi Y; Taghikhani M; Nahavandian B; Rafati S
    Indian J Med Res; 2009 Nov; 130(5):533-41. PubMed ID: 20090101
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vaccination of full-length HPV16 E6 or E7 protein inhibits the growth of HPV16 associated tumors.
    Li YL; Qiu XH; Shen C; Liu JN; Zhang J
    Oncol Rep; 2010 Nov; 24(5):1323-9. PubMed ID: 20878127
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel "priming-boosting" strategy for immune interventions in cervical cancer.
    Liao S; Zhang W; Hu X; Wang W; Deng D; Wang H; Wang C; Zhou J; Wang S; Zhang H; Ma D
    Mol Immunol; 2015 Apr; 64(2):295-305. PubMed ID: 25575128
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine.
    Welters MJ; Kenter GG; Piersma SJ; Vloon AP; Löwik MJ; Berends-van der Meer DM; Drijfhout JW; Valentijn AR; Wafelman AR; Oostendorp J; Fleuren GJ; Offringa R; Melief CJ; van der Burg SH
    Clin Cancer Res; 2008 Jan; 14(1):178-87. PubMed ID: 18172269
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunization of protein HPV16 E7 in fusion with mouse HSP70 inhibits the growth of TC-1 cells in tumor bearing mice.
    Li YL; Liu J; Liu JN; Zhang J
    Vaccine; 2011 Aug; 29(35):5959-62. PubMed ID: 21722685
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel self-assembled nanoparticle vaccine with HIV-1 Tat₄₉₋₅₇/HPV16 E7₄₉₋₅₇ fusion peptide and GM-CSF DNA elicits potent and prolonged CD8⁺ T cell-dependent anti-tumor immunity in mice.
    Tang J; Yin R; Tian Y; Huang Z; Shi J; Fu X; Wang L; Wu Y; Hao F; Ni B
    Vaccine; 2012 Feb; 30(6):1071-82. PubMed ID: 22178528
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunization of mice by the co-administration of codon-optimized HPV16 E7 and lL12 genes against HPV16-associated cervical cancer.
    Ajorloo M; Alamdary A; Soleimanjahi H; El Boulani A; Khanizadeh S; Nikoo HR
    Microb Pathog; 2019 Jul; 132():20-25. PubMed ID: 31004722
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.